22.71 USD
▲+0.82+3.75%
盘后 23.30 +2.60%
2026-11-19
市值
$3.68B
市盈率
—
EPS
-1.38
股息率
—
52 周区间
7.83 – 34.39
成交量
1.81M
Beta
1.22
目标价
47.00
52W 低 7.8352W 高 34.39
价格走势
公司简介
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ...